Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

Zurko, Joanna C; Johnson, Bryon D; Aschenbrenner, Emilie; Fenske, Timothy S; Hamadani, Mehdi; Hari, Parameswaran; Shah, Nirav N · JAMA Oncol · 2022

case_series · Level IV

Where this comes from

Abstract

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

Medical subject headings